Lima, Peru, 15 April 2022 - The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), recently received registration approval from the General Directorate of Medicine, Supplies and Drugs (DIGEMID) in Peru.
Firehawk Liberty™ is a drug-eluting stent (DES) that features strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy.
Firehawk Liberty™ allows for the precise release of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, ensuring the effectiveness of the drug, whilst significantly reducing the drug dosage. In addition, it features innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the vessel wall apposition.
Firehawk Liberty™ is currently approved in a number of countries and regions, including Egypt, Belarus, Saudi Arabia, South Korea, Brazil, Colombia, India and the European Union. In 2021, MicroPort®’s drug-eluting stents obtained 14 initial registrations in 12 countries or regions,, and have been approved for marketing in a total of 36 countries or regions.
The approval of Firehawk Liberty™ in Peru marks that MicroPort® will continuously deepen the globalised branding and operation strategy based on local language families by consistently implementing the operation model of “globalisation in operational strategy, localised implementation, deployment with diversification, and unified positioning”, thereby realising global deployment through effective integration of resources and markets around the world, which in turn will bring the products of MicroPort® to more countries or regions and benefit patients and doctors around the world.
About Shanghai MicroPort Medical (Group) Co., Ltd.
Shanghai MicroPort Medical (Group) Co., Ltd. is a subsidiary of MicroPort Scientific Corporation (“MicroPort®”, Stock code: 00853.HK). As a leader in high-end innovative medical solutions, MicroPort® places emphasis on the human dimension while integrating the pursuit of perfection and innovation into the corporate DNA. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians with higher-quality, innovative high-end medical devices and integrated solutions.